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Haematological-oncologists in each of France, Germany, Italy, Spain and the UK, 
actively managing patients with Multiple Myeloma, were asked to complete patient 
record forms (PRF) prospectively for the next eight patients who consulted their 
clinic. In addition to clinical considerations, prescribers were asked to record the 
impact of administrative controls on their prescribing decisions as well as being 
asked attitudinal and perceptual information on the influence of payer recom-
mendations. Results: We observed national variation of the influence of payers 
on prescribing decisions. Administrative controls were cited as influencing more 
than 70% of prescribing decisions in all markets except Germany, where the figure 
was 50%. Inclusion on formulary was a strong driver of prescriber decisions about 
therapy, cited as a driver in the majority of individual decision in all markets except 
Germany. We also observed that prescribers reported that they would have selected 
an alternative treatment in around 1 in 8 patients, had administrative controls not 
been in place. Germany was the exception, where this figure is closer to 1 in 20 
individual prescribing decisions. ConClusions: This research demonstrates that 
prescribers’ behavior is strongly influenced by administrative controls to which 
payers contribute, and that there are differences between Germany and the other 
4 markets investigated. Further research will establish whether differences reflect 
actual differences in the nature and impact of controls, or simply greater alignment 
between prescribers’ and payers’ objectives or opinions in Germany. This has the 
potential to inform discussions between prescribers and payers about rational use 
of medicines and patients’ access to medicines.
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objeCtives: Tiered pricing, also referred to as differential pricing or equitable 
pricing, involves adjusting drug prices to the purchasing power of consumers in 
different geographical or socio-economic segments. Traditionally, tiered pricing 
strategies have aimed to improve access to medicines in the developing world. 
There has been increasing interest from manufacturers and payers in employing 
such strategies for oncology agents, but improved patient access and commercial 
success has been variable. This research aims to understand the challenges and 
opportunities associated with implementing tiered pricing for oncology agents and 
the factors that may contribute to a successful strategy. Methods: Systematically 
analyse a set of case studies in order to clearly identify current practice and trends 
in tiered pricing strategies for cancer drugs in key emerging markets. Evaluate vari-
ous strategies based on publically available information and identify drivers for 
improved patient access and commercial success. Results: Emerging markets 
represent a complex environment and a number of challenges such as physical 
and informational arbitrage impact a differential pricing strategy. Strategies driven 
by short-term profitability objectives have usually failed and those that have not 
addressed the inefficient distribution channels in emerging markets have also strug-
gled to gain traction. Additionally, a poor knowledge of demand elasticity has often 
limited impact. ConClusions: Tiered pricing strategies represent a powerful tool 
for improving patient access to cancer drugs in emerging markets. Every tiered 
pricing strategy needs to be tailored to each product and market/ segment. A clear 
understanding of the objectives driving the strategy, the potential pricing tools 
applicable in a market, the distribution channels and methods to mitigate risk are 
key to improving patient access and supporting commercial success.
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objeCtives: Oncology medicines reimbursed in France have a fixed price whereas 
the benefits vary across patient groups. Pricing models aligned to the benefit for 
patients open an interesting concept, but they need to be supported by reliable and 
standardised metrics aligned with heath authorities ‘expectation. The Personalised 
Reimbursement Models (PRM) pilots aim to establish an infrastructure validated by 
the National Data Privacy Committee to collect existing data of metastatic breast 
cancer patients (mBC) taking trastuzumab and leverage preliminary analytics to 
evaluate the relevance of this approach. Methods: mBC patients at 14 pilots cen-
tres recorded in the Electronic Pharmacy Record (EPR) system with at least one 
trastuzumab claim between January 2011 to October 2014 that were not enrolled in 
a clinical trial were selected. Data related to demographics, disease description, drug 
usage and clinical outcomes were collected in the EPR. These data were controlled, 
cleaned and centralised in an anonymous and secure way through an accredited 
hosting provider. Results: 510 mBC patients taking trastuzumab were identified. 
21 of the 30 target variables were available in the EPR with a mean of 3.5% percent of 
missing data and results that were consistent with literature. Unavailable variables 
have been identified in other data sources within centres or could be added to the 
EPR by updating and enhancing the health information systems. The recruitment of 
around 100 additional centres began in January 2015 following a sampling method 
designed to ensure the representativeness of clinical practice. ConClusions: Pilot 
study has validated technical and legal feasibility of the PRM infrastructure imple-
mentation and the quality of the outputs. Over time, PRM will deliver robust and 
standardised real world evidence that could be used to implement models that will 
support more flexible pricing strategies and help ensure patient access to innovative 
treatments delivered in different indications.
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to identify patients diagnosed with ovarian cancer and were taking treatment from 
January 2001 to December 2013 were included in the study. All patients were ≥ 18 
years of age and continuously enrolled in the same health plan at least for a year. 
Descriptive statistics and chi-square tests were performed on the data. Results: 
There were a total of 2,562 patients that met the study inclusion criteria. There 
were 1,718 (67.10%) patients < 65 years of age (adult) and 844 (32.90%) ≥ 65 years of 
age (geriatric). There was a significant difference (p< 0.05) between the mean ages 
of two groups (52.48±9.76 vs 73.08±6.62 years). The mean length of stay of adult 
patients was lower than (p< 0.05) geriatric patients (1.23±1.57 vs 1.45±2.67 days). 
There were more patients in adult group in the East (23.5% vs 21.0%) and MidWest 
(30.3% vs 27.6%) regions but no significant difference was found (p> 0.05). On aver-
age, patients were continuously enrolled in the same health plan for 62.00±37.03 
vs 66.64±35.21 months and submitted 567.10±574.49 vs 740.58±629.71 claims with 
a significant difference (p< 0.05) between the two groups. Patients on average were 
charged by the provider $533.62±2232.26 vs $492.09±2123.24 for their ovarian can-
cer treatment (p< 0.05) during the study period. However, the actual paid amount 
by the health plan was $225.25±1215.97 vs $136.79±962.99 with a significant dif-
ference between the groups (p< 0.05). ConClusions: The majority of the patients 
were < 65 years of age and were paid higher amount by the health plan for the 
treatment of ovarian cancer.
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objeCtives: The objective of this study is to assess the characteristics and health 
care resource utilization of patients diagnosed with prostate cancer. Methods: A 
large US administrative retrospective claims database was used to identify patients 
diagnosed with prostate cancer and were taking treatment in the USA from January 
2001 to December 2013 were included in the study. All patients were ≥ 18 years of 
age and continuously enrolled in the same health plan at least for a year. Descriptive 
statistics and chi-square tests were performed on the data. Results: There were a 
total of 19,279 patients that met the study inclusion criteria. Of these, 6,359 (33.0%) 
patients were < 65 years of age (adult) and 12,920 (67.0%) ≥ 65 years of age (geriat-
ric). There was a significant difference (p< 0.05) in the mean ages of two groups 
(59.02±4.99 vs 74.55±6.55 years). There were more patients in adult group in the 
MidWest (28.5% vs 23.6%) and South (38.3% vs 36.4%) regions with a significant 
difference between the groups (p< 0.05). On average, patients were continuously 
enrolled in the same health plan for 65.37±35.91 vs 65.80±32.84 months (p> 0.05) and 
submitted 366.85±381.92 vs 492.37±431.42 claims during the study period (p< 0.05). 
Patients on average were charged by the provider $763.84±3003.48 vs $595.56±2207.71, 
the allowed amount by the health plan was $343.75±1496.33 vs $270.81±1380.54 and 
the actual paid amount by the health plan was $309.67±1294.90 vs $165.08±768.48 
with a significant difference between the groups (p< 0.05). ConClusions: The 
majority of the patients were geriatric. On average, geriatric patients were charged 
less by the provider and actual paid amount by the health plan was less compared 
to adult patients for the treatment of prostate cancer.
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objeCtives: The objective of this study is to assess the characteristics and health 
care resource utilization of patients diagnosed with malignant neoplasm of rec-
tum. Methods: A large US administrative retrospective claims database was used 
to identify patients diagnosed with malignant neoplasm of rectum and were tak-
ing treatment in the USA from January 2001 to December 2013 were included in 
the study. All patients were ≥ 18 years of age and continuously enrolled in the 
same health plan at least for a year. Descriptive statistics and chi-square tests 
were performed on the data. Results: There were a total of 2,461 patients that 
met the study inclusion criteria. Of these, 1,695 (68.87%) were < 65 years of age 
(adult) and 766 (31.13%) were ≥ 65 years of age (geriatric). There was no difference 
(p> 0.05) in the distribution of males (57.2% vs 57.0%) and a significant difference 
(p< 0.01) between the mean ages of two groups (53.49±7.50 vs 72.73±5.26 years) was 
found. The mean length of stay between the groups (1.96±4.37 vs 1.96±4.56 days) 
was almost same. There were more patients in adult group in the East (31.3% vs 
22.7%) and South (38.3% vs 37.3%) regions with a significant difference (p< 0.05) 
between the groups. On average, patients were continuously enrolled in the same 
health plan for 63.50±36.74 vs 64.43±32.40 months and submitted 640.33±580.25 
vs 680.26±598.82 claims with no significant difference (p> 0.05) between the two 
groups. Patients on average were charged by the provider $611.69±2771.24 vs 
$639.36±3554.90 (p> 0.05), allowed amount by the health plan was $284.71±1515.83 
vs $287.31±1996.25 (p> 0.05) and the actual paid amount by the health plan was 
$268.84±1490.76 vs $145.21±1068.87 (p< 0.05). ConClusions: The majority of the 
patients were adult and health plans paid higher amount for these patient groups 
compared to geriatric patients for the treatment of malignant neoplasms of rectum.
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objeCtives: To assess the extent to which prescribing decisions are influenced by 
payer implemented controls. Methods: Data were drawn from the Adelphi Disease 
Specific Programme (DSP) in Multiple Myeloma conducted in Q1 2015. DSPs are cross 
sectional surveys of physicians and their consulting patients. Fifty Haematologists/
